Article
Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.
Clinical lung cancer - 1 Dec 2024
Lara Matthew S, Riess Jonathan W, Goldman Jonathan W, Jiang Fei, Bivona Trever G, Blakely Collin M
Abstract excerpt
INTRODUCTION: MET tyrosine kinase inhibitor (TKI) therapy is associated with improved outcomes in patients with nonsmall cell lung cancer (NSCLC) harboring a MET alteration, including MET exon 14 (METex14) skipping mutation, MET amplification, or MET fusion. However, primary or acquired resistance to TKI therapy ultimately develops. In preclinical models, hyperactivation of MAPK signaling was shown to promote...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.